Sildenafil for pulmonary arterial hypertension

Area of Science:

• Cardiology
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) involves progressive pulmonary vasculature obliteration, leading to right-ventricular failure and mortality.
• Current PAH therapies target endothelial dysfunction, addressing prostacyclin and nitric oxide deficiencies and endothelin excess.

Purpose of the Study:

• To evaluate the efficacy and safety of sildenafil in treating pulmonary arterial hypertension.
• To explore sildenafil's mechanism of action, focusing on the nitric oxide/cyclic GMP pathway.

Main Methods:

• Investigated sildenafil's impact on established measures of PAH, including 6-minute walk distance and hemodynamic parameters.
• Reviewed clinical trial data and post-marketing surveillance for adverse events and tolerability.

Main Results:

• Sildenafil demonstrated favorable responses in 6-minute walk tests and hemodynamic assessments in PAH patients.
• The drug is generally well-tolerated, with mild and transient adverse events reported.
• Sildenafil has received regulatory approval (e.g., FDA, EMA) for PAH treatment under the trade name Revatio.

Conclusions:

• Sildenafil represents an effective and safe therapeutic option for pulmonary arterial hypertension.
• Its ease of administration and favorable safety profile contribute to its clinical utility in managing PAH.